Category: Advanced Accelerator Applications

  • Novartis’ radioligand therapy meets phase 3 prostate cancer trial target

    Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist pharma Endocyte looks to have been justified.  The big Swiss pharma added this drug to its pipeline after it swooped for Endocyte and so far it looks like a good piece of business, with potential blockbuster sales […]